Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MABp1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MTD | EXPERIMENTAL | The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored. |
| Name | Type | Description |
|---|---|---|
| MABp1 | DRUG | 0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops. |
Inclusion Criteria: * pathologically confirmed advanced malignancy that is metastatic or unresectable and which is refractory to standard therapy or for which thee is no standard therapy that provides benefits for \>/= 3 months * measurable or non-measurable disease at baseline * at least 4 weeks s...
MABp1 is an investigational small molecule developed by Johnson & Johnson (ticker JNJ) for the treatment of advanced cancers. It has been studied in a single Phase 1 first-in-man clinical trial in patients with advanced cancers, and it is not an approved therapy.
MABp1 has been evaluated for use in patients with advanced cancers. Its only clinical study to date was a first-in-man Phase 1 trial conducted in the United States in adults with advanced cancers, and the drug remains investigational rather than approved for any indication.
MABp1 is developed by Johnson & Johnson, which trades under the ticker JNJ. The company sponsored the Phase 1 first-in-man study of MABp1 in patients with advanced cancers, which was conducted in the United States.
MABp1 is in Phase 1 development. It has completed one Phase 1 first-in-man trial in patients with advanced cancers, and no later-stage trials are recorded. The drug is investigational and has not been approved for any indication.
MABp1 has been studied in one clinical trial, NCT01021072, titled A First in Man Study of MABp1 in Patients With Advanced Cancers. That Phase 1 trial enrolled 52 patients in the United States, was uncontrolled, and has been completed.
MABp1 is not approved and remains an investigational drug in Phase 1 clinical development. Its only recorded study, NCT01021072, was a completed first-in-man Phase 1 trial in 52 patients with advanced cancers conducted in the United States.